| | AstraZeneca initiates phase III clinical development of fostamatinib for the treatment of rheumatoid arthritis | | | AstraZeneca today announced the enrollment of the first patient in the phase III clinical development programme for fostamatinib, a novel oral syk inhibitor. The phase III programme, called OSKIRA (Oral Syk Inhibition in Rheumatoid Arthritis), is designed to investigate fostamatinib as a treatment for rheumatoid arthritis (RA) in patients with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX). | |  View full press release | | | This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us. | | | |
No comments:
Post a Comment